COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary

TY - JOUR

T1 - COVID-19 and the multidisciplinary care of patients with lung cancer

T2 - an evidence-based review and commentary

AU - Round, Thomas

AU - L’Esperance, Veline

AU - Bayly, Joanne

AU - Brain, Kate

AU - Dallas, Lorraine

AU - Edwards, John G.

AU - Haswell, Thomas

AU - Hiley, Crispin

AU - Lovell, Natasha

AU - McAdam, Julia

AU - McCutchan, Grace

AU - Nair, Arjun

AU - Newsom-Davis, Thomas

AU - Sage, Elizabeth K.

AU - Navani, Neal

N1 - Funding Information: Funding information T.R. is funded by a National Institute for Health Research (NIHR) Doctoral Research Fellowship (DRF) (ref.: DRF-2016-09-054) and was previously supported by a Royal Marsden Partners (RMP) Research Fellowship. T.R. also has an honorary contract with the National Cancer Registration and Analysis Service, Public Health England (PHE). J.B. is supported by the NIHR Applied Research Collaboration South London at King’s College London. V.L. is funded by a National Institute for Health Research (NIHR) Doctoral Research Fellowship (DRF) (ref.: DRF-2017-10-132). N. N. is supported by an MRC Clinical Academic Research Partnership (MR/T02481X/1). This work was partly undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. T.R. and N.N. are collaborators on a Cancer Research UK (CRUK) Early Diagnosis Advisory Group (EDAG) project award (ref.: C11558/A25623); ‘Identifying missed actionable events in the natural history of lung cancer prior to diagnosis in primary care and implementing them in a learning health system in NE London’. T.R., N.N. and K.B. collaborated on a COVID-19 and lung cancer educational webinar funded by Astra Zeneca, but with no editorial input from the funder. The views expressed are those of the authors and not necessarily those of their institutions or funders, including MRC, NIHR, NHS, RMP, Public Health England (PHE) or the Department of Health and Social Care. Publisher Copyright: © 2021, The Author(s), under exclusive licence to Cancer Research UK. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/8/31

Y1 - 2021/8/31

N2 - Delivering lung cancer care during the COVID-19 pandemic has posed significant and ongoing challenges. There is a lack of published COVID-19 and lung cancer evidence-based reviews, including for the whole patient pathway. We searched for COVID-19 and lung cancer publications and brought together a multidisciplinary group of stakeholders to review and comment on the evidence and challenges. A rapid review of the literature was undertaken up to 28 October 2020, producing 144 papers, with 113 full texts screened. We focused on new primary data collection (qualitative or quantitative evidence) and excluded case reports, editorials and commentaries. Following exclusions, 15 published papers were included in the review and are summarised. They included one qualitative paper and 14 quantitative studies (surveys or cohort studies), with a total of 2295 lung cancer patients data included (mean study size 153 patients; range 7–803). Review of current evidence and commentary included awareness and help-seeking; lung cancer screening; primary care assessment and referral; diagnosis and treatment in secondary care, including oncology and surgery; patient experience and palliative care. Cross-cutting themes and challenges were identified using qualitative methods for patients, healthcare professionals and service delivery, with a clear need for continued studies to guide evidence-based decision-making.

AB - Delivering lung cancer care during the COVID-19 pandemic has posed significant and ongoing challenges. There is a lack of published COVID-19 and lung cancer evidence-based reviews, including for the whole patient pathway. We searched for COVID-19 and lung cancer publications and brought together a multidisciplinary group of stakeholders to review and comment on the evidence and challenges. A rapid review of the literature was undertaken up to 28 October 2020, producing 144 papers, with 113 full texts screened. We focused on new primary data collection (qualitative or quantitative evidence) and excluded case reports, editorials and commentaries. Following exclusions, 15 published papers were included in the review and are summarised. They included one qualitative paper and 14 quantitative studies (surveys or cohort studies), with a total of 2295 lung cancer patients data included (mean study size 153 patients; range 7–803). Review of current evidence and commentary included awareness and help-seeking; lung cancer screening; primary care assessment and referral; diagnosis and treatment in secondary care, including oncology and surgery; patient experience and palliative care. Cross-cutting themes and challenges were identified using qualitative methods for patients, healthcare professionals and service delivery, with a clear need for continued studies to guide evidence-based decision-making.

UR - http://www.scopus.com/inward/record.url?scp=85105555336&partnerID=8YFLogxK

U2 - 10.1038/s41416-021-01361-6

DO - 10.1038/s41416-021-01361-6

M3 - Review article

AN - SCOPUS:85105555336

SN - 0007-0920

VL - 125

SP - 629

EP - 640

JO - British journal of cancer

JF - British journal of cancer

IS - 5

ER -